metaLinear is a biotechnology company focused on the identification and validation of new drug targets for difficult to treat bacterial infections.
Why we like the business
metaLinear's founder has extensive scientific and business expertise in the commercialisation of protein engineering that underpins metaLinear's business. The development of new therapies to treat multi-drug resistant infections is a priority for governments, healthcare providers and industry. metaLinear's technology has the potential to identify important new drug targets and accelerate the development of new classes of antibiotics for the treatment of serious infections.